@article{meier_hmg-coa_2000,
	title = {{HMG}-{CoA} reductase inhibitors and the risk of fractures},
	volume = {283},
	issn = {0098-7484},
	abstract = {CONTEXT: Recent animal studies have suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) increase bone formation, volume, and density. It is unknown whether use of statins is associated with a decreased risk of fractures in humans.
OBJECTIVE: To determine whether exposure to statins, fibrates, or other lipid-lowering drugs is associated with reduced bone fracture risk.
DESIGN: Population-based, nested case-control analysis.
SETTING: The UK-based General Practice Research Database (GPRD), comprising some 300 practices, with data collection from the late 1980s until September 1998.
SUBJECTS: Within a base population of 91,611 individuals aged at least 50 years (28,340 individuals taking lipid-lowering drugs, 13,271 untreated individuals with a diagnosis of hyperlipidemia, and 50,000 randomly selected individuals without diagnosis of hyperlipidemia), we identified 3940 case patients who had a bone fracture and 23,379 control patients matched for age (+/-5 years), sex, general practice attended, calendar year, and years since enrollment in the GPRD.
MAIN OUTCOME MEASURES: Use of statins, fibrates, or other lipid-lowering drugs in case patients vs control patients.
RESULTS: After controlling for body mass index, smoking, number of physician visits, and corticosteroid and estrogen use, current use of statins was associated with a significantly reduced fracture risk (adjusted odds ratio [OR], 0.55; 95\% confidence interval [CI], 0.44-0.69) compared with nonuse of lipid-lowering drugs. Current use of fibrates or other lipid-lowering drugs was not related to a significantly decreased bone fracture risk (adjusted OR, 0.87; 95\% CI, 0.70-1.08 and adjusted OR, 0.76; 95\% CI, 0.41-1.39, respectively).
CONCLUSIONS: This study suggests that current exposure to statins is associated with a decreased risk of bone fractures in individuals age 50 years and older. This finding has a potentially important public health impact and should be confirmed further in controlled prospective trials. JAMA. 2000;283:3205-3210},
	language = {eng},
	number = {24},
	journal = {JAMA},
	author = {Meier, C. R. and Schlienger, R. G. and Kraenzlin, M. E. and Schlegel, B. and Jick, H.},
	month = jun,
	year = {2000},
	pmid = {10866867},
	keywords = {Aged, Bone and Bones, Case-Control Studies, Female, Fractures, Bone, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Logistic Models, Male, Middle Aged, Multivariate Analysis, Risk},
	pages = {3205--3210}
}

{"_id":"oLMAEEkqHxdcLRJwm","bibbaseid":"meier-schlienger-kraenzlin-schlegel-jick-hmgcoareductaseinhibitorsandtheriskoffractures-2000","downloads":0,"creationDate":"2017-08-15T09:38:10.674Z","title":"HMG-CoA reductase inhibitors and the risk of fractures","author_short":["Meier, C. R.","Schlienger, R. G.","Kraenzlin, M. E.","Schlegel, B.","Jick, H."],"year":2000,"bibtype":"article","biburl":"http://bibbase.org/zotero/veegee78","bibdata":{"bibtype":"article","type":"article","title":"HMG-CoA reductase inhibitors and the risk of fractures","volume":"283","issn":"0098-7484","abstract":"CONTEXT: Recent animal studies have suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) increase bone formation, volume, and density. It is unknown whether use of statins is associated with a decreased risk of fractures in humans. OBJECTIVE: To determine whether exposure to statins, fibrates, or other lipid-lowering drugs is associated with reduced bone fracture risk. DESIGN: Population-based, nested case-control analysis. SETTING: The UK-based General Practice Research Database (GPRD), comprising some 300 practices, with data collection from the late 1980s until September 1998. SUBJECTS: Within a base population of 91,611 individuals aged at least 50 years (28,340 individuals taking lipid-lowering drugs, 13,271 untreated individuals with a diagnosis of hyperlipidemia, and 50,000 randomly selected individuals without diagnosis of hyperlipidemia), we identified 3940 case patients who had a bone fracture and 23,379 control patients matched for age (+/-5 years), sex, general practice attended, calendar year, and years since enrollment in the GPRD. MAIN OUTCOME MEASURES: Use of statins, fibrates, or other lipid-lowering drugs in case patients vs control patients. RESULTS: After controlling for body mass index, smoking, number of physician visits, and corticosteroid and estrogen use, current use of statins was associated with a significantly reduced fracture risk (adjusted odds ratio [OR], 0.55; 95% confidence interval [CI], 0.44-0.69) compared with nonuse of lipid-lowering drugs. Current use of fibrates or other lipid-lowering drugs was not related to a significantly decreased bone fracture risk (adjusted OR, 0.87; 95% CI, 0.70-1.08 and adjusted OR, 0.76; 95% CI, 0.41-1.39, respectively). CONCLUSIONS: This study suggests that current exposure to statins is associated with a decreased risk of bone fractures in individuals age 50 years and older. This finding has a potentially important public health impact and should be confirmed further in controlled prospective trials. JAMA. 2000;283:3205-3210","language":"eng","number":"24","journal":"JAMA","author":[{"propositions":[],"lastnames":["Meier"],"firstnames":["C.","R."],"suffixes":[]},{"propositions":[],"lastnames":["Schlienger"],"firstnames":["R.","G."],"suffixes":[]},{"propositions":[],"lastnames":["Kraenzlin"],"firstnames":["M.","E."],"suffixes":[]},{"propositions":[],"lastnames":["Schlegel"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Jick"],"firstnames":["H."],"suffixes":[]}],"month":"June","year":"2000","pmid":"10866867","keywords":"Aged, Bone and Bones, Case-Control Studies, Female, Fractures, Bone, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Logistic Models, Male, Middle Aged, Multivariate Analysis, Risk","pages":"3205--3210","bibtex":"@article{meier_hmg-coa_2000,\n\ttitle = {{HMG}-{CoA} reductase inhibitors and the risk of fractures},\n\tvolume = {283},\n\tissn = {0098-7484},\n\tabstract = {CONTEXT: Recent animal studies have suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) increase bone formation, volume, and density. It is unknown whether use of statins is associated with a decreased risk of fractures in humans.\nOBJECTIVE: To determine whether exposure to statins, fibrates, or other lipid-lowering drugs is associated with reduced bone fracture risk.\nDESIGN: Population-based, nested case-control analysis.\nSETTING: The UK-based General Practice Research Database (GPRD), comprising some 300 practices, with data collection from the late 1980s until September 1998.\nSUBJECTS: Within a base population of 91,611 individuals aged at least 50 years (28,340 individuals taking lipid-lowering drugs, 13,271 untreated individuals with a diagnosis of hyperlipidemia, and 50,000 randomly selected individuals without diagnosis of hyperlipidemia), we identified 3940 case patients who had a bone fracture and 23,379 control patients matched for age (+/-5 years), sex, general practice attended, calendar year, and years since enrollment in the GPRD.\nMAIN OUTCOME MEASURES: Use of statins, fibrates, or other lipid-lowering drugs in case patients vs control patients.\nRESULTS: After controlling for body mass index, smoking, number of physician visits, and corticosteroid and estrogen use, current use of statins was associated with a significantly reduced fracture risk (adjusted odds ratio [OR], 0.55; 95\\% confidence interval [CI], 0.44-0.69) compared with nonuse of lipid-lowering drugs. Current use of fibrates or other lipid-lowering drugs was not related to a significantly decreased bone fracture risk (adjusted OR, 0.87; 95\\% CI, 0.70-1.08 and adjusted OR, 0.76; 95\\% CI, 0.41-1.39, respectively).\nCONCLUSIONS: This study suggests that current exposure to statins is associated with a decreased risk of bone fractures in individuals age 50 years and older. This finding has a potentially important public health impact and should be confirmed further in controlled prospective trials. JAMA. 2000;283:3205-3210},\n\tlanguage = {eng},\n\tnumber = {24},\n\tjournal = {JAMA},\n\tauthor = {Meier, C. R. and Schlienger, R. G. and Kraenzlin, M. E. and Schlegel, B. and Jick, H.},\n\tmonth = jun,\n\tyear = {2000},\n\tpmid = {10866867},\n\tkeywords = {Aged, Bone and Bones, Case-Control Studies, Female, Fractures, Bone, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypolipidemic Agents, Logistic Models, Male, Middle Aged, Multivariate Analysis, Risk},\n\tpages = {3205--3210}\n}\n\n","author_short":["Meier, C. R.","Schlienger, R. G.","Kraenzlin, M. E.","Schlegel, B.","Jick, H."],"key":"meier_hmg-coa_2000","id":"meier_hmg-coa_2000","bibbaseid":"meier-schlienger-kraenzlin-schlegel-jick-hmgcoareductaseinhibitorsandtheriskoffractures-2000","role":"author","urls":{},"keyword":["Aged","Bone and Bones","Case-Control Studies","Female","Fractures","Bone","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Hypolipidemic Agents","Logistic Models","Male","Middle Aged","Multivariate Analysis","Risk"],"downloads":0},"search_terms":["hmg","coa","reductase","inhibitors","risk","fractures","meier","schlienger","kraenzlin","schlegel","jick"],"keywords":["aged","bone and bones","case-control studies","female","fractures","bone","humans","hydroxymethylglutaryl-coa reductase inhibitors","hypolipidemic agents","logistic models","male","middle aged","multivariate analysis","risk"],"authorIDs":[],"dataSources":["FmCWXwJibZiWNzpdc"]}